Scancell Holdings Plc Director Dealing (0261L)
27 Aprile 2020 - 05:39PM
UK Regulatory
TIDMSCLP
RNS Number : 0261L
Scancell Holdings Plc
27 April 2020
27 April 2020
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer announces that Vulpes Life Science Fund, a
person closely associated with Martin Diggle, Non- Executive
Director, has sold 500,000 ordinary shares of 0.1p each ('Ordinary
Shares') in the Company on 24 April 2020 at a price of 8p per
share. Following the sale, Vulpes Life Science Fund holds
80,049,311 ordinary shares representing 17.2% of the company.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH
THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Vulpes Life Science Fund
------------------------------- ----------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Person closely associated with Martin Diggle,
Non-Executive Director
------------------------------- ----------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------
a) Name Scancell Holdings plc
------------------------------- ----------------------------------------------
b) LEI 2138008RXEG856SNP666
------------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence each
financial instrument,
type of instrument
------------------------------- ----------------------------------------------
b) Identification Code GB00B63D3314
------------------------------- ----------------------------------------------
c) Nature of the transaction Sale of Ordinary Shares
------------------------------- ----------------------------------------------
d) Price(s) and volume(s) 500,000 Ordinary Shares
8 pence per Ordinary Share
------------------------------- ----------------------------------------------
e) Aggregated information
- Aggregated volume N/A (single transaction)
- Price
------------------------------- ----------------------------------------------
f) Date of the transaction 24 April 2020
------------------------------- ----------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
------------------------------- ----------------------------------------------
- ENDS -
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For more information, please contact:
+44 (0)20 3727
Scancell Holdings plc 1000
Dr John Chiplin, Chairman
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0) 20 7886
and Joint Broker) 2500
Corporate Finance: Freddy Crossley, Emma
Earl
Corporate Broking: James Stearns
+44 (0)20 3727
FTI Consulting 1000
Simon Conway
Natalie Garland-Collins
Notes for Editors
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They have the potential to be
used as monotherapy or in combination with checkpoint inhibitors
and other agents. This platform has the potential to enhance tumour
destruction, prevent disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK (CRUK) for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
AvidiMab(TM) is a patent protected technology platform which
increases the avidity of human antibodies by promoting non-covalent
Fc-Fc interactions. This modification induces the direct tumour
cell killing properties of Scancell's anti-glycan monoclonal
antibodies (mAbs) but has broad potential to increase the avidity
or potency of any therapeutic monoclonal antibody including those
being developed for autoimmune diseases, as well as cancer.
In response to the COVID-19 pandemic, Scancell has turned its
clinical expertise in cancer to produce a simple, safe,
cost-effective and scalable vaccine to induce both durable T cell
responses and virus neutralising antibodies against SARS-Cov-2, the
virus that causes COVID-19. The Company believes this combined T
cell and antibody approach should give more potent and long-lasting
responses, ultimately leading to better protection.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEASLXADKEEFA
(END) Dow Jones Newswires
April 27, 2020 11:39 ET (15:39 GMT)
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Mar 2023 a Mar 2024